Table 1.
Preoperative characteristics of patients and disease in the whole series and stratified according to period of recruitment.
| Variables | Whole Series | Period 1 (2004–2009) |
Period 2 (2010–2015) |
Period 3 (2015–2020) |
a vs. b | a vs. c | b vs. c | a vs. b vs. c | |
|---|---|---|---|---|---|---|---|---|---|
| 1212 | 293 | 353 | 566 | ||||||
| Age, median (range) | years | 60 (37–80) | 59 (32–80) | 62 (31–83) | 61 (26–89) | NS | NS | NS | NS |
| Gender, n (%) | NS | NS | NS | NS | |||||
| Male | 678 (55.9) | 166 (56.7) | 191 (54.1) | 321 (56.6) | |||||
| Female | 534 (44.1) | 127 (43.3) | 162 (45.9) | 245 (43.4) | |||||
| ASA Score, n (%) | NS | 0.05 | 0.04 | 0.04 | |||||
| I/II | 773 (63.8) | 197 (67.2) | 241 (68.3) | 335 (59.2) | |||||
| III/IV | 439 (36.2) | 96 (32.8) | 112 (31.7) | 231 (40.8) | |||||
| Neoadjuvant CT, n (%) | 970 (80) | 211 (72) | 299 (84.7) | 460 (81.2) | 0.03 | 0.04 | NS | 0.03 | |
| CT regimen, n (%) | 0.04 | NS | NS | 0.04 | |||||
| Oxaliplatin based | 583 (48.1) | 123 (42) | 171 (48.4) | 289 (51.1) | |||||
| Irinotecan based | 439 (36.2) | 76 (25.9) | 155 (43.9) | 208 (36.7) | |||||
| Associated biological therapy | 537 (44.3) | 89 (30.4) | 155 (43.9) | 293 (51.8) | 0.02 | 0.01 | 0.05 | 0.03 | |
| Number of CT cycles, median (range) | 6 (1–23) | 9 (1–16) | 7 (1–23) | 6 (3–19) | 0.04 | 0.03 | NS | 0.05 | |
| Associated comorbidites, n (%) | 582 (48) | 101 (34.5) | 167 (47.3) | 314 (55.5) | 0.03 | 0.04 | NS | 0.03 | |
| Features of non-tumorous parenchyma, n (%) | NS | 0.03 | NS | 0.04 | |||||
| Normal | 538 (44.4) | 95 (32.4) | 167 (47.3) | 276 (48.8) | |||||
| Steatosis | 252 (20.8) | 77 (26.3) | 50 (14.2) | 125 (22.1) | |||||
| CALI | 422 (34.8) | 121 (41.3) | 136 (38.5) | 165 (29.1) | |||||
| Primary tumor location, n (%) | NS | NS | NS | NS | |||||
| Right colon | 279 (23) | 81 (27.6) | 96 (27.2) | 102 (18) | |||||
| Left colon | 351 (29) | 94 (32.1) | 108 (30.6) | 149 (26.4) | |||||
| Rectum | 582 (48) | 118 (40.3) | 149 (42.2) | 315 (55.6) | |||||
| Staging, n (%) | NS | NS | NS | NS | |||||
| T1 | 47 (3.9) | 11 (3.8) | 18 (5.1) | 18 (3.2) | |||||
| T2 | 534 (44.1) | 127 (43.3) | 154 (43.6) | 253 (44.8) | |||||
| T3 | 530 (43.7) | 131 (44.7) | 145 (41.1) | 254 (44.8) | |||||
| T4 | 101 (8.3) | 24 (8.2) | 36 (10.2) | 41 (7.2) | |||||
| Grading, n (%) | NS | NS | NS | NS | |||||
| G1 | 96 (7.9) | 27 (9.2) | 31 (8.8) | 38 (6.7) | |||||
| G2 | 922 (76.1) | 201 (68.6) | 266 (75.4) | 455 (80.4) | |||||
| G3 | 194 (16) | 65 (22.2) | 56 (15.9) | 73 (12.9) | |||||
| Nodal status, n (%) | NS | NS | NS | NS | |||||
| N0 | 583 (48.1) | 141 (48.1) | 172 (48.7) | 270 (47.7) | |||||
| N1 | 488 (40.3) | 117 (39.9) | 134 (38) | 237 (41.9) | |||||
| N2 | 141 (11.6) | 35 (11.9) | 47 (13.3) | 59 (10.4) | |||||
| Presentation, n (%) | NS | 0.04 | 0.04 | 0.04 | |||||
| Synchronous | 446 (36.8) | 91 (31.1) | 117 (33.1) | 238 (42) | |||||
| Metachronous | 766 (63.2) | 202 (68.9) | 236 (66.9) | 328 (58) | |||||
| Number of liver lesions, median (range) | 3 (1–44) | 2 (1–12) | 2(1–44) | 3 (1–32) | NS | NS | NS | NS | |
| Nodularity, n (%) | NS | 0.02 | 0.01 | 0.02 | |||||
| Monofocal | 530 (43.7) | 162 (55.3) | 170 (48.2) | 198 (34.9) | |||||
| Multifocal | 682 (56.3) | 131 (44.7) | 183 (51.8) | 368 (65.1) | |||||
| Lobe distibution of metastases, n (%) | NS | 0.03 | 0.05 | 0.04 | |||||
| Unilobar | 630 (52) | 184 (62.8) | 191 (54.1) | 255 (45.1) | |||||
| Bilobar | 582 (48) | 109 (37.2) | 162 (45.9) | 311 (54.9) | |||||
| Redo liver surgery, n (%) | 378 (31.2) | 65 (22.2) | 105 (29.7) | 208 (36.8) | 0.04 | 0.01 | 0.04 | 0.03 | |
| Extrahepatic disease, n (%) | 133 (11) | 14 (4.8) | 30 (10.8) | 81 (14.3) | 0.04 | 0.01 | 0.03 | 0.03 | |
| Liver met diameter, median (range) | 2.9 (0.5–11) | 2.7 (0.5–9) | 2.9 (0.5–11) | 2.8 (0.5–13) | NS | NS | NS | NS | |
| Clinical Risk Score, median (range) | 3 (1–5) | 2 (1–5) | 3 (1–5) | 4 (1–5) | NS | 0.03 | NS | 0.05 | |
| CEA level, median (range) | 35.6 (2–299) | 31.9 (2–135) | 35.6 (2–276) | 44.5 (2–1045) | NS | NS | NS | NS | |